IL1A and COVID-19: These results expand on our previous experience about the higher efficacy of IL-1 and IL-6 blockade in COVID-19 patients with elevated C-reactive protein and indicate that anti-cytokine treatments should be tailored not only on the inflammatory phenotype but also on the respiratory status in order to implement the selection of patients most likely to benefit from cytokine-targeted therapies (3, 20).